Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,550 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Choice Clear all
Completed Phase 3 Interventional Results available

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

NCT01564784
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
96
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

NCT01125904
View directory record Official record
Conditions
Healthy
Interventions
crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Sep 3, 2026, 11:20 PM EDT
Completed No phase listed Observational

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

NCT03511235
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
Up to 80 Years · Male only
Enrollment
774 participants
Timeline
2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Concord, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Early Phase 1 Interventional Results available

Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer

NCT02383043
View directory record Official record
Conditions
Active Cocaine Users
Interventions
Cocaine, Sustained Release d-Amphetamine
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
21 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533
View directory record Official record
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
36
States / cities
Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 3, 2026, 11:20 PM EDT
Completed No phase listed Observational

Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

NCT06662825
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
16 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 3, 2026, 11:20 PM EDT
Withdrawn Not applicable Interventional

Study of Endoscopic Versus Open Surgery for Urinary Reflux

NCT00830479
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
Anti-reflux surgery, Endoscopic injection
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Contraceptive Choice at the Time of Uterine Evacuation

NCT02836561
View directory record Official record
Conditions
Contraception
Interventions
Telephone message
Other
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 3, 2026, 11:20 PM EDT
Completed No phase listed Observational

Virology Follow up Study in Subjects Previously Treated With Telaprevir

NCT00916474
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Keiki (Pediatric) Produce Prescription (KPRx) Program Hawaii

NCT05442424
View directory record Official record
Conditions
Malnutrition, Child, Obesity, Food Selection, Nutrition Poor
Interventions
Produce Voucher, Wait-List Control
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
2 Years to 8 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 3, 2026, 11:20 PM EDT
Terminated Phase 1 Interventional

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

NCT05389462
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ADCT-601, Gemcitabine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 3, 2026, 11:20 PM EDT
Enrolling by invitation No phase listed Observational

Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

NCT06624189
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis
Interventions
Auto-pended bot liver ultrasound order
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

NCT02292654
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 3, 2026, 11:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 11:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774
View directory record Official record
Conditions
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions
Tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874
View directory record Official record
Conditions
Smoking Cessation
Interventions
APD356-lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
31
States / cities
Encino, California • Escondido, California • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions
Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 3, 2026, 11:20 PM EDT
Terminated Phase 2 Interventional Results available

Reduced Intensity AlloTransplant For Osteopetrosis

NCT00638820
View directory record Official record
Conditions
Osteopetrosis
Interventions
Stem Cell or Umbilical Cord Blood Transplantation, Campath, Busulfan, Clofarabine, Total Lymphoid Irradiation
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 3, 2026, 11:20 PM EDT
Completed No phase listed Observational

Voices Of Individuals: Challenges and Experiences Of bvFTD

NCT04060082
View directory record Official record
Conditions
Frontotemporal Dementia, Frontotemporal Degeneration, Frontotemporal Dementia, Behavioral Variant, FTD
Interventions
Telephone Interview
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 3, 2026, 11:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Responses After Human Subject Challenge With Sand Fly Bites

NCT01289977
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 3, 2026, 11:20 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

NCT01562899
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
Interventions
MEK162, AMG 479
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 3, 2026, 11:20 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936
View directory record Official record
Conditions
Lymphoma
Interventions
Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
24
States / cities
Berkeley, California • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 11:20 PM EDT
Completed Not applicable Interventional

Study of Screening Self-management Goals on Short Term Behavior Change

NCT01936311
View directory record Official record
Conditions
Patient Health Behaviors
Interventions
Self-management goal elicitation
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 3, 2026, 11:20 PM EDT